arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Computer Science · Information Systems

Simplifying switch to second line ART: Predicted effect of defining failure of first-line efavirenz-based regimens in sub-Saharan Africa by a single viral load > 1000 copies/ml

Shroufi, A, Van Cutsem, G, Cambiano, V, Bansi-Matharu, L, Duncan, K, Murphy, RA, Maman, D, Phillips, A

UCL Discovery (University College London)

See on the map

Abstract

Background: Many individuals failing first-line antiretroviral therapy (ART) in sub-Saharan
\nAfrica never initiate second-line antiretroviral treatment (ART) or do so after significant
\ndelay. For people on ART with a viral load (VL) > 1000 copies/ml, the World Health
\nOrganization (WHO) recommends a second VL measurement 3 months after the first VL and
\nenhanced adherence support. Switch to a second-line regimen is contingent upon a
\npersistently elevated VL > 1000 copies/ml. Delayed second-line switch places patients at
\nincreased risk for opportunistic infections and mortality.
\nMethods: To assess the potential benefits of a simplified second-line ART switch strategy,
\nwe use an individual-based model of HIV transmission, progression and the effect of ART
\nwhich incorporates consideration of adherence and drug resistance to compare predicted
\noutcomes of 2 policies, defining 1st-line regimen failure for patients on efavirenz based ART
\nas either (i) two consecutive VL values > 1000 copies/ml, with the second after an enhanced
\nadherence intervention (implemented as per current WHO guidelines) or (ii) a single VL
\nvalue > 1000 copies/ml. We simulated a range of setting-scenarios reflecting the breadth of
\nthe sub-Saharan African HIV epidemic, taking into account potential delays in defining
\nfailure and switch to second line ART.
\nFindings: The use of a single VL > 1000 copies/ml to define ART failure would lead to a
\nhigher proportion of persons with NNRTI resistance switched to second-line ART (65% vs
\n48%; difference 17% [90% range 14% - 20%]), resulting in a median 18% reduction in the
\nrate of AIDS-related death over setting scenarios (90% range 6% - 30%; from a median of
\n3·1 to 2·5 per 100 person years) over 3 years. The simplified strategy also is predicted to
\nreduce the rate of AIDS conditions by a median of 31% (90% Range 8% - 49%) among
\npeople on 1st line ART with a viral load > 1000 copies/ml in the past 6 months. For a
\ncountry of 10 million adults (and a median of 880,000 people with HIV), we estimate that
\nthis approach would lead to a median of 1,322 (90% range 67 to 3,513) AIDS deaths averted
\nper year over three years. For South Africa this would represent around 10,215 deaths averted
\nannually.
\nInterpretation: As a step towards reducing unnecessary mortality associated with delayed
\nsecond line ART switch, defining failure of first-line efavirenz-based regimens as a single
\nVL>1000 copies/ml should be considered.
\nFunding: No specific funding was obtained for the analysis or writing of this manuscript.

More like this